Share this video  

ESMO 2022 | Biomarker analysis and updated results from PROpel

Fred Saad, MD, FRCS, University of Montreal Hospital Center, Montreal, Canada, presents biomarker analysis and updated results from the Phase III PROpel trial (NCT03732820) of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Meaningful improvements in radiographic progression-free survival was observed in the experimental arm in all assessed biomarker subgroups. Updated results show a continuing trend towards improved overall survival and support a superior clinical benefit with abiraterone + olaparib vs abiraterone + placebo as first-line therapy for patients with mCRPC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.